GE Healthcare has introduced its new molecular imaging technologies that will allow clinicians to offer customised and quantitative results to patients.
The technologies included the Discovery MI system and Discovery NM/CT 670 CZT, which feature mdoern digital detectors.
Xeleris 4.0 is the new nuclear medicine workstation that supports Discovery NM/CT 670 CZT and other nuclear medicine systems. It will assist clinicians in achieving customisable, easy-to-read reports across multiple care areas.
Discovery MI system is a PET/CT system that features a combination of time-of-flight (TOF) and Q.Clear technologies, enabling clinicians to undertake studies such as quantitative brain studies by its expanded field-of-view (FOV).
Discovery MI is equipped with low-yield tracer capabilities with protocols to reduce doses by up to 50%, which allows the clinicians to undertake research without altering the image quality. This subsequently expands the clinician's diagnostic service offerings.
The system is fitted with the new LightBurst Digital Detector that delivers an improved volumetric resolution, enabling small lesion detectability and has a highest national electrical manufacturers association (NEMA) sensitivity.
It is also incorporated with the new diagnostic CT innovations with a high spatial resolution, with no increase in image noise with ASiR-V.
Discovery MI's smart metal artifact reduction (MAR) removes streaks and shadows from metal artifacts, saving time previously spent in correcting images.
GE's Discovery NM/CT 670 CZT is designed for improved lesion detection and image quality while ensuring patient comfort. The new imaging system is equipped with a new digital detector powered by cadmium zinc telluride (CZT) technology, which directly converts photons into a digital signal that reduces signal loss and noise.
The combined technologies will enable clinicians to detect smaller lesions and accurately quantify them using its increased spatial and contrast resolution.
It facilitates the completion of multiple scans in a single visit while reducing the injected dose or the scan time by 50%, which improves the patient experience.
Image: GE's one of next-generation molecular imaging systems. Photo: courtesy of General Electric.